Skip to main content
. 2014 Jan 10;2014(1):CD007470. doi: 10.1002/14651858.CD007470.pub3

3. Characteristics of included trials (III).

Characteristic
Study ID 		D3 
 [IU] D2 
 [IU] 1α(OH)D 
 [µg] 1,25(OH)2D 
 [µg] Ca 
 [mg] Regimen Route Treatment
 [years] Follow‐up
 [years]
Aloia 2005 800
 2000       1200‐1500a Daily Oral 3 3
Avenell 2004 800       1000b Daily Oral 1 1
Avenell 2012 800       500b Daily Oral 3.75 6.2
Baeksgaard 1998 560       1000 Daily Oral 2 2
Bischoff 2003 800       1200a Daily Oral 0.25 0.25
Bjorkman 2007 400
 1200       500a Daily Oral 0.5 0.5
Bolton‐Smith 2007 400       1000 Daily Oral 2 2
Brazier 2005 800       1000 Daily Oral 1 1
Broe 2007   200
 400
 600
 800       Daily Oral 0.42 0.42
Brohult 1973 100,000         Daily Oral 1 1
Burleigh 2007 800       1200a Daily Oral 0.08 0.08
Campbell 2005 50,000
100,000		         Monthly Oral 1 1
Chapuy 1992 800       1200 Daily Oral 1.5 4
Chapuy 2002 800       1200 Daily Oral 2 2
Chel 2008 600
 4200
 18.000       800
 1600 Daily
 Weekly
 Monthly Oral 0.33 0.33
Cherniack 2011 2000       1200a Daily Oral 0.5 0.5
Cooper 2003   10,000     1000a Weekly Oral 2 2
Corless 1985   9000       Daily Oral 0.75 0.75
Daly 2008 800       1000 Daily Oral 2 3.5
Dawson‐Hughes 1997 700       500 Daily Oral 3 3
Dukas 2004     1     Daily Oral 0.75 0.75
Flicker 2005   1000
 10,000     600a Daily
 Weekly Oral 2 2
Gallagher 2001       0.5   Daily Oral 3 5
Glendenning 2012 150,000         Three‐monthly Oral 0.5 0.75
Grady 1991       0.5   Daily Oral 0.5 0.5
Grimnes 2011 20,000         Twice weekly Oral 0.5 0.5
Harwood 2004 800 300,000     1000 Single dose
 daily Intramuscular
Oral		 1 1
Jackson 2006 400       1000 Daily Oral 7 7
Janssen 2010 400       500a Daily Oral 0.5 0.5
Komulainen 1999 300       500 Daily Oral 5 5
Krieg 1999 880       1000 Daily Oral 2 2
Kärkkäinen 2010 800       1000 Daily Oral 3 3
Lappe 2007 1000       1400‐1500b Daily Oral 4 4
Larsen 2004 400       1000 Daily Oral 3.5 3.5
Latham 2003 300,000         Single dose Oral 0.003 0.5
Law 2006   100,000       Four‐monthly Oral 0.83 0.83
Lehouck 2012 100,000         Monthly Oral 1 1
Lips 1996 400         Daily Oral 3.5 3.5
Lips 2010 8400       500a weekly Oral 0.31 0.31
Lyons 2007   100,000       Four‐monthly Oral 3 3
Meier 2004 500       500 Daily Oral 0.5 1
Mochonis 2006 300       1200b Daily Oral 1 1
Ooms 1995 400         Daily Oral 2 2
Ott 1989       0.5
 2 1000a Daily Oral 2 2
Porthouse 2005 800       1000 Daily Oral 2 2
Prince 2008   1000     1000a Daily Oral 1 1
Sanders 2010 500,000         Yearly Oral 2.96 2.96
Sato 1997     1   300a Daily Oral 0.5 0.5
Sato 1999a     1     Daily Oral 1.5 1.5
Sato 1999b     1     Daily Oral 1 1
Sato 2005a   1000       Daily Oral 2 2
Schleithoff 2006 2000       500a Daily Oral 0.75 1.25
Smith 2007   300,000       Yearly Intramuscular 3 3
Trivedi 2003 100,000         Four‐monthly Oral 5 5
Witham 2010   100,000        10‐weekly Oral 0.38 0.38
Zhu 2008   1000     1200b Daily Oral 5 5

aEqual dose of calcium was administered to a control group
 bCalcium was tested singly in one arm of the trial as well as combined with vitamin D; placebo or no intervention group of the trial was not supplemented with calcium
 
 1α(OH)D: alfacalcidol; 1,25(OH)2D: calcitriol; IU: international units; µg: microgram